Modern Dietary Fat Intakes in Disease Promotion

Part of the series Nutrition and Health pp 185-191


Recent Cholesterol-Lowering Drug Trials: New Data, New Questions

  • Michel de LorgerilAffiliated withLaboratoire TIMC-IMAG, UMR 5525, Cœur and Nutrition, Faculté de Médecine, Université Joseph Fourier – Grenoble 1, CNRSDomaine de la Merci Email author 

* Final gross prices may vary according to local VAT.

Get Access

Key Points

• The cholesterol-lowering drug trials recently published were either negative (ENHANCE, SEAS, GISSI-HF) or obviously biased and therefore not credible (JUPITER).

• New data strongly suggest that the results of previous, highly positive trials with statins in the secondary prevention of coronary heart disease published between 1994 and 2004 and that were used to issue guidelines for medical practitioners should be reviewed carefully and considered somewhat suspect.


Cholesterol-lowering drugs Heart disease Cholesterol Drug trials